View Older Stories View More Recent Stories

Aug 25, 2022 07:31AM TG Therapeutics (TGTX) Reports Publication of Results from ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab
Aug 25, 2022 07:30AM TG Therapeutics Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Published in The New England Journal of Medicine
Aug 8, 2022 07:30AM TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
Aug 5, 2022 07:30AM TG Therapeutics to Host Conference Call on Second Quarter 2022 Financial Results and Business Update
Jun 27, 2022 07:31AM TG Therapeutics (TGTX) Reports Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab
Jun 27, 2022 07:30AM TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology
Jun 3, 2022 07:30AM TG Therapeutics (TGTX) Presents Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab
Jun 3, 2022 07:30AM TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Ann
May 31, 2022 07:30AM TG Therapeutics (TGTX) Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS
May 31, 2022 07:30AM TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS
May 26, 2022 07:30AM TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annua
May 20, 2022 07:30AM TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
Apr 26, 2022 07:30AM TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference
Apr 18, 2022 09:23AM Pre-Open Stock Movers 04/18: Casa Systems and Natus Medical Higher; TG Therapeutics and Nektar Lower (more...)
Apr 15, 2022 08:31AM TG Therapeutics (TGTX) Voluntarily Withdraws BLA/sNDA for U2 to Treat Patients with CLL and SLL
Apr 15, 2022 08:30AM TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL
Apr 6, 2022 07:30AM TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting
Apr 4, 2022 07:44AM TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the American Academy of Neurology Annual Meeting
Mar 10, 2022 08:16AM TG Therapeutics (TGTX) Announces FDA Set ADCOM Meeting for April 22, 2022
Mar 10, 2022 08:15AM TG Therapeutics Announces Scheduling of Planned Oncologic Drug Advisory Committee Meeting
Mar 4, 2022 07:31AM TG Therapeutics (TGTX) Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting
Mar 4, 2022 07:30AM TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting
Mar 3, 2022 08:00AM TG Therapeutics (TGTX) Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ
Mar 3, 2022 08:00AM TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patients with CLL and SLL
Mar 1, 2022 07:31AM TG Therapeutics (TGTX) Provides Business Update, Reports Q4
Mar 1, 2022 07:30AM TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
Feb 25, 2022 07:33AM TG Therapeutics (TGTX) Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis
Feb 25, 2022 07:30AM TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple
Feb 24, 2022 07:30AM TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business Update
Feb 15, 2022 07:31AM TG Therapeutics (TGTX) to Present Data from ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis
Feb 15, 2022 07:30AM TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Mu
Jan 24, 2022 07:30AM TG Therapeutics to Participate in the B. Riley Securities 2022 Virtual Oncology Investor Conference
Jan 5, 2022 07:30AM TG Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
Jan 4, 2022 07:30AM TG Therapeutics Expands Term Loan Facility With Hercules Capital to $200 Million
Dec 14, 2021 07:33AM TG Therapeutics (TGTX) Announces Data from the UNITY-CLL Phase 3 Trial Presented at ASH
Dec 14, 2021 07:30AM TG Therapeutics Announces Data from the UNITY-CLL Phase 3 Trial Presented at the 63rd American Society of Hematology (ASH) Annual Meeting
Dec 14, 2021 07:15AM TG Therapeutics (TGTX) Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of MS
Dec 14, 2021 07:15AM TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis
Dec 13, 2021 07:30AM TG Therapeutics Announces Data Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting
Dec 10, 2021 07:30AM TG Therapeutics Recaps Schedule of Data Presentations at the Upcoming 63rd American Society of Hematology (ASH) Annual Meeting
Nov 30, 2021 07:33AM TG Therapeutics (TGTX) Issues Regulatory Update
Nov 30, 2021 07:30AM TG Therapeutics Provides Regulatory Update
Nov 15, 2021 07:30AM TG Therapeutics to Participate in the Jefferies London Healthcare Conference
Nov 9, 2021 07:30AM TG Therapeutics to Participate in the B. Riley Securities Fall 2021 Growth Biotech Best Ideas Virtual Series
Nov 4, 2021 09:34AM TG Therapeutics Highlights Data Selected for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting
Nov 4, 2021 07:00AM TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
Nov 1, 2021 07:30AM TG Therapeutics to Host Conference Call on Third Quarter 2021 Financial Results and Business Update
Oct 14, 2021 10:46AM TG Therapeutics (TGTX) Announces Data for Ublituximab in MS Presented at ECTRIMS
Oct 14, 2021 10:45AM TG Therapeutics Announces Data for Ublituximab in Multiple Sclerosis Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Sep 30, 2021 07:31AM TG Therapeutics (TGTX) Submits BLA to FDA for Ublituximab as Treatment for Patients with Relapsing Forms of Multiple Sclerosis
View More Recent Stories View Older Stories